A major protein-bound ligand in the serum of chronic hemodialysis patients was isolated from heat-deproteinized uremic serum by "high-performance" liquid chromatography (HPLC). The isolated compound was identified as 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid by use of liquid secondary-ion mass spectrometry and gas chromatographymass spectrometry. On HPLC, an authentic sample of this compound showed a retention time identical to that of the protein-bound ligand peak. The concentration of the furancarboxylic acid in serum, as estimated by HPLC, is markedly greater in chronic hemodialysis patients than in normal subjects.
Samples and Sample Preparation
Serum samples were obtained from eight healthy subjects and from 27 uremic patients maintained on chronic hemodialysis. Venous blood was collected from the uremic patients immediately before hemodialysis. We deproteinized the serum samples according to the method of Mabuchi and Nakahashi (17) by boiling 2 mL of sample at 10000 for 5 mm. On cooling to room temperature, the sample gelled. We triturated the gelatinous sample mechanically with a microspatula, then centrifuged it for 30 mm at 4280 x g to remove protein. After ifitering the supernate through another 0.45-pm (pore-size) ifiter (Biofield Co. Ltd., Tokyo, Japan), we injected 100 p.L of it onto the HPLC column.
To determine the ligands that were not bound to serum protein, we passed uremic serum through a CF-25 ultrafiltration membrane ifiter (Amicon Co., Lexington, MA), then chromatographed 100 pL of the ultrafiltrate.
HPLC Apparatus and Chromatographic Conditions
We used a chromatographic assembly from Jasco Co. Ltd., Tokyo, Japan. This consisted of a Model Trirotar-V pump equipped with a Rheodyne 7125 injection valve and a variable-wavelength detector (Uvidec-100V; Jasco Co. Ltd.). The column packing was Chemcosorb 5-ODS-H (particle size 5-pm, 300 x 7.5 mmi.d.), from Chemco Co. Ltd., Osaka, Japan. We eluted the column isocratically with acetonitrile/ water/trifluoroacetic acid (40/60/0.08, by vol) at a flow rate of 2.2 mLlmin at room temperature, and monitored the column effluent at 270 mn.
Quantification Assay
To quantify the furancarboxylic acid, we used the same analytical procedure as that used to proffle the compounds in the uremic sera. We prepared a standard curve by assaying solutions of various amounts of 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid in acetonitrile/water (4/6 by vol). Determination of the peak areas of the samples, relative to the peak area of the standard, yielded the linear regression equation, y = 0.465x + 0.015 (r = 0.99985).
We assessed analytical recovery by assaying five 2-mL aliquots of control serum to which known amounts of the furancarboxylic acid had been added and comparing the peak areas from the heat-deproteinized samples with those obtained from a direct injection of the same amount of authentic standard in acetronile/water (4/6 by vol). Recoveries exceeded 85% in most instances. identifying a protein-bound ligand. We injected 0.3 mL of the supernate of the heat-deproteinized serum into the HPLC system and so obtained a sufficient amount of sample for GC-MS analysis. The HPLC eluate was evaporated under reduced pressure and a solution of diazomethane in diethyl ether was added to the residue dropwise until the reaction mixture became yellow. The reaction mixture was left at room temperature for 12 h, then evaporated under nitrogen. After reconstituting the residue in 15 pL of ethyl acetate, we injected 5-pL aliquots into the GC-MS. Authentic 3-carboxy-4-methyl-5-propyl-2-propiomc acid, methylated by the same procedure, was redissolved in ethyl acetate to give a concentration of 5 g/L and 1 pL was injected into the GC-MS.
Gas Chromatography-Mass Spectrometry (GC-MS)
We used a Model 9A gas chromatograph coupled to a GSMS-QP1000 quadrupole mass spectrometer (both from Shimadzu Co. Ltd., Kyoto, Japan). The mass spectra from automatic repetitive scanning at 3-s intervals were recorded over the mass range nilz 50-350 and stored on a floppy disk. The (IC conditions were as follows. A 1-m glass column packed with Gas Chrom Qcoated with 2% OV-101, 100-120 mesh (Shimadzu Co.); carrier gas, helium; flow rate 50 mu miii; column temperature, 80#{176}C for 1 miii, then programmed to 270 #{176}C at 5 #{176}C/min; injection block temperature, 
Liquid Secondary-Ion
Mass Spectrometry (siMs)
The HPLC fraction obtained from 1.1 mL of heat-deproteinized serum supernate was evaporated and the residue was redissolved in 20 pL of water. We mixed 1 pL of this solution with about 1 pL of glycerol on a silver-plated sms probe.
For liquid sis we used a double-focusing Model M-80B mass spectrometer fitted with a Model M-8089 high-field magnet, SIMS source, and Model M-0101 data system (all from Hitachi Co. Ltd., Tokyo, Japan). Operating conditions were: primary ion, Xe4; accelerating voltage, 8 kV (primary) and -3kV (secondary); and source at ambient temperature. Figure 1 shows typical liquid chromatograms for equal volumes of supernate from heat-deproteinized uremic serum, ultrafiltrate of uremic serum, and supernate from heat-deproteinized nonuremic serum.
Results
The characteristic peak being investigated, designated as "peak F' by Mabuchi and Nakahashi (17), is eluted 17.6 miii after sample injection. The heat-deproteinized samples from chronic hemodialysis patients (Figure lb) show high concentrations of peak P for sera, but a just-detectable peak P in the ultrafiltrate of this uremic serum (Figure lc) . Evidently the substance corresponding to peak P is tightly bound to protein. To clarify the structure of this protein-bound ligand accumulated in uremic serum, we collected and combined eluates of serum samples containing peak P, concentrated this by evaporation, and then subjected the residue to mass spectral analysis. Figure 2 shows the positive and negative ion SIMS spectra for this residue. Determination of molecular mass is less straightforward from the spectrum of positive ion mode than of the negative ion mode. The peak at m/z 239 observed in the negative ionization mode corresponds to the quasi-molecular ion, EM -H1, of the intact protein-bound ligand, whereas the peaks at mfz 245 and 223 in the positive ionization mode could be assigned to the dehydrated ions [(M + Na) -H2O] and [MH -H20]4, respectively.
Methylation with diazomethane followed by (IC-MS was a powerful technique for making structural identifications. The electron-ionization mass spectrum of the (IC peak eluted at 17.0 mm exhibited EM]4 at mlz 268 and fragments  at mJz 239, 237, 208, 195, 179, and 147 (Figure 3b) , consistent with its assignment as 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid dimethylester (18). The total and selected ion monitoring chromatograms of methylated residue from the uremic serum showed responses identical with those for the authentic dimethylester (Figure 3) . In fact, the electron-ionization mass spectrum of the authentic furancarboxylic acid dimethylester (Figure 4a ) was identical with that shown in Figure 4b . Furthermore, the HPLC retention time for the authentic furancarboxylic acid was identical to that of peak P (Figure la) .
We quantified the furancarboxylic acid by HPLC without using an internal standard. In nonuremic sera the mean concentration of furancarboxylic acid was 6.6 (SD 2.8) mg/L (n = 8), as compared with the 38.6 (SD 11.4) mgfL in heatdeproteinized uremic serum (n = 27). 
Discussion
The decreased binding of various acidic drugs to protein in sera from uremic patients is generally attributed to the accumulation of endogenous metabolites that bind to serum albumin and competitively inhibit the binding of drugs.
Mabuchi and Nakahashi (17), using HPLC, considered peak P in their chromatograms to correspond to a major inhibitor of drug-binding in uremia. Using the same HPLC method, we have now isolated peak P from uremic serum, and have identified it as 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid by liquid sns, and (IC-MS. We also used the HPLC method to quantify the concentrations of furancarboxylic acid in sera from uremic patients and healthy subjects. Deproteinization of serum by heating at 100#{176}C for 5 mm was appropriate for this procedure: not only is it easy and rapid, it also gives high analytical recoveries of added authentic compound. The concentrations of 3-carboxy-4-methyl-5-propyl-2-ftu-anpropionic acid in serum were highly increased in all uremic patients as compared with healthy subjects, and the acid was bound to serum protein, being almost absent from ultrafiltrate of uremic serum. The accumulated 3-carboxy-4-methy-5-propyl-2-furanpropionic acid in uremic serum cannot be removed efficiently by conventional hemodialysis, because the lipophilic acids bind tightly to serum protein (<5% is unbound in uremic serum).
3-Carboxy-4-methyl-5-propyl-2-furanpropionic acid, first detected in urine from healthy subjects by Spiteller and Spiteller (18), was also detected and quantified in sera from uremic patients by Liebich et al. (19) , who used preparative thin-layer chromatography and (IC-MS. Their quantillcation method is laborious and time-consuming.
Our HPLC method is rapid, and requires only 20 zL of supernate from heat-deproteinized serum.
